|
1
|
Sinn BV, von Minckwitz G, Denkert C,
Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G,
Belau A, Thommsen C, et al: Evaluation of Mucin-1 protein and mRNA
expression as prognostic and predictive markers after neoadjuvant
chemotherapy for breast cancer. Ann Oncol. 24:2316–2324. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haddon L and Hugh J: MUC1-mediated
motility in breast cancer: A review highlighting the role of the
MUC1/ICAM-1/Src signaling triad. Clin Exp Metastasis. 32:393–403.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carmon L, Avivi I, Kovjazin R, Zuckerman
T, Dray L, Gatt ME, Or R and Shapira MY: Phase I/II study exploring
ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal
peptide vaccine, in multiple myeloma patients. Br J Haematol.
169:44–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kovjazin R, Horn G, Smorodinsky NI,
Shapira MY and Carmon L: Cell surface-associated anti-MUC1-derived
signal peptide antibodies: implications for cancer diagnostics and
therapy. PLoS One. 9:e854002014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mohit E, Hashemi A and Allahyari M: Breast
cancer immunotherapy: Monoclonal antibodies and peptide-based
vaccines. Expert Rev Clin Immunol. 10:927–961. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
von Mensdorff-Pouilly S, Verstraeten AA,
Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest
PJ, Meijer S and Hilgers J: Survival in early breast cancer
patients is favorably influenced by a humoral immune response to
polymorphic epithelial mucin. J Clin Oncol. 18:574–583. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hamanaka Y, Suehiro Y, Fukui M, Shikichi
K, Imai K and Hinoda Y: Circulating anti-MUC1 IgG antibodies as a
favorable prognostic factor for pancreatic cancer. Int J Cancer.
103:97–100. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reddish M, MacLean GD, Koganty RR,
Kan-Mitchell J, Jones V, Mitchell MS and Longenecker BM: Anti-MUC1
class I restricted CTLs in metastatic breast cancer patients
immunized with a synthetic MUC1 peptide. Int J Cancer. 76:817–823.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang CK, Katsara M and Apostolopoulos V:
Strategies used for MUC1 immunotherapy: Human clinical studies.
Expert Rev Vaccines. 7:963–975. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
von Mensdorff-Pouilly S, Moreno M and
Verheijen RH: Natural and induced humoral responses to MUC1.
Cancers (Basel). 3:3073–3103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pericleous LM, Richards J, Epenetos AA,
Courtenay-Luck N and Deonarain MP: Characterisation and
internalisation of recombinant humanized HMFG-1 antibodies against
MUC1. Br J Cancer. 93:1257–1266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thie H, Toleikis L, Li J, von Wasielewski
R, Bastert G, Schirrmann T, Esteves IT, Behrens CK, Fournes B,
Fournier N, et al: Rise and fall of an anti-MUC1 specific antibody.
PLos One. 6:e159212011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pastan I, Hassan R, FitzGerald DJ and
Kreitman RJ: Immunotoxin treatment of cancer. Annu Rev Med.
58:221–237. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Teicher BA: Antibody-drug conjugate
targets. Curr Cancer Drug Targets. 9:982–1004. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Edge SB and Compton CC: The American joint
committee on cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang Y and Wang L, Zhang P, Wei H, Gao R,
Liu X, Yu Y and Wang L: Detection of circulating anti-mucin 1
(MUC1) antibodies in breast tumor patients by indirect
enzyme-linked immunosorbent assay using a recombinant MUC1 protein
containing six tandem repeats and expressed in Escherichia coli.
Clin Vaccine Immunol. 17:1903–1908. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Klee GG and Schreiber WE: MUC1
gene-derived glycoprotein assays for monitoring breast cancer (CA
15-3, CA 27.29, BR): Are they measuring the same antigen? Arch
Pathol Lab Med. 128:1131–1135. 2004.PubMed/NCBI
|
|
18
|
Nakamura H, Hinoda Y, Nakagawa N,
Makiguchi Y, Itoh F, Endo T and Imai K: Detection of circulating
anti-MUC1 mucin core protein antibodies in patients with colorectal
cancer. J Gastroenterol. 33:354–361. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Croce MV, Isla-Larrain MT, Demichelis SO,
Gori JR, Price MR and Segal-Eiras A: Tissue and serum MUC1 mucin
detection in breast cancer patients. Breast Cancer Res Trea.
81:195–207. 2003. View Article : Google Scholar
|
|
20
|
Richards ER, Devine PL, Quin RJ, Fontenot
JD, Ward BG and McGuckin MA: Antibodies reactive with the protein
core of MUC1 mucin are present in ovarian cancer patients and
healthy women. Cancer Immunol Immunother. 46:245–252. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Treon SP, Maimonis P, Bua D, Young G, Raje
N, Mollick J, Chauhan D, Tai YT, Hideshima T, Shima Y, et al:
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody
levels in patients with multiple myeloma. Blood. 96:3147–3153.
2000.PubMed/NCBI
|
|
22
|
von Mensdorff-Pouilly S, Gourevitch MM,
Kenemans P, Verstraeten AA, Litvinov SV, van Kamp GJ, Meijer S,
Vermorken J and Hilgers J: Humoral immune response to polymorphic
epithelial mucin (MUC1) in patients with benign and malignant
breast tumors. Eur J Cancer. 32:1325–1331. 1996. View Article : Google Scholar
|
|
23
|
Revello MG, Gorini G and Gerna G: Clinical
evaluation of a chemiluminescence immunoassay for determination of
immunoglobulin g avidity to human cytomegalovirus. Clin Diagn Lab
Immunol. 11:801–805. 2004.PubMed/NCBI
|
|
24
|
Schoenardie ER, Scaini CJ, Avila LF,
Sperotto RL, Borsuk S, Felicetti CD, Pepe M and Berne ME:
Determination of IgG avidity in BALB/c mice experimentally infected
with Toxocara canis. Rev Bras Parasitol Vet. 23:403–406. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moazzezy N, Farahany TZ, Oloomi M and
Bouzari S: Relationship between preoperative serum CA 15–3 and CEA
levels and clinicopathological parameters in breast cancer. Asian
Pac J Cancer Prev. 15:1685–1688. 2014. View Article : Google Scholar : PubMed/NCBI
|
